Paul J Hengeveld

8PUBLICATIONS
13CO-AUTHORS
Rehabilitation engineeringPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCellular immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 06, 2025
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.

Paul J Hengeveld, Joyce Schilperoord-Vermeulen, P Martijn Kolijn

|Jul 31, 2023
Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis.

P Martijn Kolijn, Florentin Späth, Mouhamad Khouja

|Jul 21, 2023
Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.

Paul J Hengeveld, Hendrik Veelken, Cornelis A M van Bergen

|Jul 03, 2023
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.

P J Hengeveld, J Schilperoord-Vermeulen, M Y van der Klift

|Sep 09, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.

Paul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn

|May 18, 2022
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110.

Paul J Hengeveld, Y Emre Ertem, Julie M N Dubois

Pageof 2

Frequent Collaborators

7 joint publications

Anton W Langerak

6 joint publications

Peter E Westerweel

6 joint publications

Mark-David Levin

3 joint publications

Arnon P Kater